Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Nat Commun ; 13(1): 7090, 2022 11 19.
Article in English | MEDLINE | ID: mdl-36402763

ABSTRACT

Peroxisome proliferator-activated receptor γ (PPARγ) is the master regulator of adipocyte differentiation, and mutations that interfere with its function cause lipodystrophy. PPARγ is a highly modular protein, and structural studies indicate that PPARγ domains engage in several intra- and inter-molecular interactions. How these interactions modulate PPARγ's ability to activate target genes in a cellular context is currently poorly understood. Here we take advantage of two previously uncharacterized lipodystrophy mutations, R212Q and E379K, that are predicted to interfere with the interaction of the hinge of PPARγ with DNA and with the interaction of PPARγ ligand binding domain (LBD) with the DNA-binding domain (DBD) of the retinoid X receptor, respectively. Using biochemical and genome-wide approaches we show that these mutations impair PPARγ function on an overlapping subset of target enhancers. The hinge region-DNA interaction appears mostly important for binding and remodelling of target enhancers in inaccessible chromatin, whereas the PPARγ-LBD:RXR-DBD interface stabilizes the PPARγ:RXR:DNA ternary complex. Our data demonstrate how in-depth analyses of lipodystrophy mutants can unravel molecular mechanisms of PPARγ function.


Subject(s)
Lipodystrophy , PPAR gamma , Humans , PPAR gamma/genetics , PPAR gamma/metabolism , Adipocytes/metabolism , Retinoid X Receptors/genetics , Retinoid X Receptors/metabolism , Lipodystrophy/metabolism , Regulatory Sequences, Nucleic Acid
2.
Biochim Biophys Acta Mol Cell Biol Lipids ; 1864(8): 1157-1167, 2019 08.
Article in English | MEDLINE | ID: mdl-31051284

ABSTRACT

BACKGROUND: Natural killer T (NKT) cells in adipose tissue (AT) contribute to whole body energy homeostasis. RESULTS: Inhibition of the glucosylceramide synthesis in adipocytes impairs iNKT cell activity. CONCLUSION: Glucosylceramide biosynthesis pathway is important for endogenous lipid antigen activation of iNKT cells in adipocytes. SIGNIFICANCE: Unraveling adipocyte-iNKT cell communication may help to fight obesity-induced AT dysfunction. Overproduction and/or accumulation of ceramide and ceramide metabolites, including glucosylceramides, can lead to insulin resistance. However, glucosylceramides also fulfill important physiological functions. They are presented by antigen presenting cells (APC) as endogenous lipid antigens via CD1d to activate a unique lymphocyte subspecies, the CD1d-restricted invariant (i) natural killer T (NKT) cells. Recently, adipocytes have emerged as lipid APC that can activate adipose tissue-resident iNKT cells and thereby contribute to whole body energy homeostasis. Here we investigate the role of the glucosylceramide biosynthesis pathway in the activation of iNKT cells by adipocytes. UDP-glucose ceramide glucosyltransferase (Ugcg), the first rate limiting step in the glucosylceramide biosynthesis pathway, was inhibited via chemical compounds and shRNA knockdown in vivo and in vitro. ß-1,4-Galactosyltransferase (B4Galt) 5 and 6, enzymes that convert glucosylceramides into potentially inactive lactosylceramides, were subjected to shRNA knock down. Subsequently, (pre)adipocyte cell lines were tested in co-culture experiments with iNKT cells (IFNγ and IL4 secretion). Inhibition of Ugcg activity shows that it regulates presentation of a considerable fraction of lipid self-antigens in adipocytes. Furthermore, reduced expression levels of either B4Galt5 or -6, indicate that B4Galt5 is dominant in the production of cellular lactosylceramides, but that inhibition of either enzyme results in increased iNKT cell activation. Additionally, in vivo inhibition of Ugcg by the aminosugar AMP-DNM results in decreased iNKT cell effector function in adipose tissue. Inhibition of endogenous glucosylceramide production results in decreased iNKT cells activity and cytokine production, underscoring the role of this biosynthetic pathway in lipid self-antigen presentation by adipocytes.


Subject(s)
Adipocytes/metabolism , Glucosylceramides/biosynthesis , Natural Killer T-Cells/metabolism , Adipocytes/cytology , Antigen Presentation , Cell Communication , Cell Line , Coculture Techniques , Cytokines/metabolism , Glucosylceramides/metabolism , Humans , Insulin Resistance , Lipids/immunology , Lymphocyte Activation , Natural Killer T-Cells/cytology
3.
Diabetologia ; 59(3): 624-33, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26661101

ABSTRACT

AIMS/HYPOTHESIS: Obesity is associated with a state of chronic low-grade inflammation that is believed to contribute to the development of skeletal muscle insulin resistance. However, the extent to which local and systemic elevation of cytokines, such as monocyte chemoattractant protein 1 (MCP-1), interferes with the action of insulin and promotes insulin resistance and glucose intolerance in muscle remains unclear. Here, we aim to investigate the effect of muscle-specific overexpression of MCP-1 on insulin sensitivity and glucose tolerance in lean and obese mice. METHODS: We used Mck-Mcp-1 transgenic (Tg) mice characterised by muscle-specific overexpression of Mcp-1 (also known as Ccl2) and elevated plasma MCP-1 levels. Mice were fed either chow or high-fat diet for 10 weeks. Numerous metabolic variables were measured, including glucose and insulin tolerance tests, muscle insulin signalling and plasma NEFA, triacylglycerol, cholesterol, glucose and insulin. RESULTS: Despite clearly promoting skeletal muscle inflammation, muscle-specific overexpression of Mcp-1 did not influence glucose tolerance or insulin sensitivity in either lean chow-fed or diet-induced obese mice. In addition, plasma NEFA, triacylglycerol, cholesterol, glucose and insulin were not affected by MCP-1 overexpression. Finally, in vivo insulin-induced Akt phosphorylation in skeletal muscle did not differ between Mcp-1-Tg and wild-type mice. CONCLUSIONS/INTERPRETATION: We show that increased MCP-1 production in skeletal muscle and concomitant elevated MCP-1 levels in plasma promote inflammation in skeletal muscle but do not influence insulin signalling and have no effect on insulin resistance and glucose tolerance in lean and obese mice. Overall, our data argue against MCP-1 promoting insulin resistance in skeletal muscle and raise questions about the impact of inflammation on insulin sensitivity in muscle.


Subject(s)
Chemokine CCL2/metabolism , Inflammation/metabolism , Muscle, Skeletal/metabolism , Animals , Chemokine CCL2/genetics , Diabetes Mellitus, Type 2/metabolism , Insulin Resistance/genetics , Insulin Resistance/physiology , Male , Mice
4.
PLoS One ; 9(5): e98343, 2014.
Article in English | MEDLINE | ID: mdl-24870614

ABSTRACT

Adipose tissue is a key regulator of energy homestasis. The amount of adipose tissue is largely determined by adipocyte differentiation (adipogenesis), a process that is regulated by the concerted actions of multiple transcription factors and cofactors. Based on in vitro studies in murine 3T3-L1 preadipocytes and human primary preadipocytes, the transcriptional cofactor and acetyltransferase Tip60 was recently identified as an essential adipogenic factor. We therefore investigated the role of Tip60 on adipocyte differentiation and function, and possible consequences on energy homeostasis, in vivo. Because homozygous inactivation results in early embryonic lethality, Tip60+/- mice were used. Heterozygous inactivation of Tip60 had no effect on body weight, despite slightly higher food intake by Tip60+/- mice. No major effects of heterozygous inactivation of Tip60 were observed on adipose tissue and liver, and Tip60+/- displayed normal glucose tolerance, both on a low fat and a high fat diet. While Tip60 mRNA was reduced to 50% in adipose tissue, the protein levels were unaltered, suggesting compensation by the intact allele. These findings indicate that the in vivo role of Tip60 in adipocyte differentiation and function cannot be properly addressed in Tip60+/- mice, but requires the generation of adipose tissue-specific knock out animals or specific knock-in mice.


Subject(s)
Adipose Tissue, White/physiology , Dosage Compensation, Genetic/genetics , Energy Metabolism/physiology , Histone Acetyltransferases/genetics , Homeostasis/physiology , Trans-Activators/genetics , 3T3-L1 Cells , Adipocytes/physiology , Animals , Blotting, Western , Cell Differentiation/genetics , DNA Primers/genetics , Energy Metabolism/genetics , HEK293 Cells , Homeostasis/genetics , Humans , Immunohistochemistry , Liver/metabolism , Lysine Acetyltransferase 5 , Mice , Mice, Inbred C57BL , Polymerase Chain Reaction
5.
Nat Commun ; 4: 2656, 2013.
Article in English | MEDLINE | ID: mdl-24141283

ABSTRACT

Transcriptional coregulators, including the acetyltransferase Tip60, have a key role in complex cellular processes such as differentiation. Whereas post-translational modifications have emerged as an important mechanism to regulate transcriptional coregulator activity, the identification of the corresponding demodifying enzymes has remained elusive. Here we show that the expression of the Tip60 protein, which is essential for adipocyte differentiation, is regulated through polyubiquitination on multiple residues. USP7, a dominant deubiquitinating enzyme in 3T3-L1 adipocytes and mouse adipose tissue, deubiquitinates Tip60 both in intact cells and in vitro and increases Tip60 protein levels. Furthermore, inhibition of USP7 expression and activity decreases adipogenesis. Transcriptome analysis reveals several cell cycle genes to be co-regulated by both Tip60 and USP7. Knockdown of either factor results in impaired mitotic clonal expansion, an early step in adipogenesis. These results reveal deubiquitination of a transcriptional coregulator to be a key mechanism in the regulation of early adipogenesis.


Subject(s)
Adipocytes/metabolism , Adipogenesis/genetics , Adipose Tissue/metabolism , Histone Acetyltransferases/genetics , Protein Processing, Post-Translational , Trans-Activators/genetics , Ubiquitin-Specific Proteases/genetics , 3T3-L1 Cells , Adipocytes/cytology , Adipose Tissue/cytology , Animals , Cell Differentiation , Gene Expression Profiling , Gene Expression Regulation , Histone Acetyltransferases/antagonists & inhibitors , Histone Acetyltransferases/metabolism , Histones/genetics , Histones/metabolism , Lysine Acetyltransferase 5 , Male , Mice , Mice, Inbred C57BL , Mitosis , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Signal Transduction , Trans-Activators/antagonists & inhibitors , Trans-Activators/metabolism , Transcription, Genetic , Ubiquitin-Specific Peptidase 7 , Ubiquitin-Specific Proteases/antagonists & inhibitors , Ubiquitin-Specific Proteases/metabolism , Ubiquitination
6.
Biochem J ; 451(1): 45-53, 2013 Apr 01.
Article in English | MEDLINE | ID: mdl-23320500

ABSTRACT

Reversible phosphorylation is a widespread molecular mechanism to regulate the function of cellular proteins, including transcription factors. Phosphorylation of the nuclear receptor PPARγ (peroxisome-proliferator-activated receptor γ) at two conserved serine residue (Ser(112) and Ser(273)) results in an altered transcriptional activity of this transcription factor. So far, only a very limited number of cellular enzymatic activities has been described which can dephosphorylate nuclear receptors. In the present study we used immunoprecipitation assays coupled to tandem MS analysis to identify novel PPARγ-regulating proteins. We identified the serine/threonine phosphatase PPM1B [PP (protein phosphatase), Mg(2+)/Mn(2+) dependent, 1B; also known as PP2Cß] as a novel PPARγ-interacting protein. Endogenous PPM1B protein is localized in the nucleus of mature 3T3-L1 adipocytes where it can bind to PPARγ. Furthermore we show that PPM1B can directly dephosphorylate PPARγ, both in intact cells and in vitro. In addition PPM1B increases PPARγ-mediated transcription via dephosphorylation of Ser(112). Finally, we show that knockdown of PPM1B in 3T3-L1 adipocytes blunts the expression of some PPARγ target genes while leaving others unaltered. These findings qualify the phosphatase PPM1B as a novel selective modulator of PPARγ activity.


Subject(s)
Adipocytes/metabolism , Cell Nucleus/metabolism , PPAR gamma/metabolism , Phosphoprotein Phosphatases/metabolism , Transcription, Genetic/physiology , 3T3-L1 Cells , Active Transport, Cell Nucleus/physiology , Adipocytes/cytology , Animals , Cell Line, Tumor , Cell Nucleus/genetics , Humans , Magnesium/metabolism , Manganese/metabolism , Mice , PPAR gamma/genetics , Phosphoprotein Phosphatases/genetics , Phosphorylation/physiology , Protein Phosphatase 2C
7.
J Clin Invest ; 122(9): 3343-54, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22863618

ABSTRACT

Lipid overload and adipocyte dysfunction are key to the development of insulin resistance and can be induced by a high-fat diet. CD1d-restricted invariant natural killer T (iNKT) cells have been proposed as mediators between lipid overload and insulin resistance, but recent studies found decreased iNKT cell numbers and marginal effects of iNKT cell depletion on insulin resistance under high-fat diet conditions. Here, we focused on the role of iNKT cells under normal conditions. We showed that iNKT cell-deficient mice on a low-fat diet, considered a normal diet for mice, displayed a distinctive insulin resistance phenotype without overt adipose tissue inflammation. Insulin resistance was characterized by adipocyte dysfunction, including adipocyte hypertrophy, increased leptin, and decreased adiponectin levels. The lack of liver abnormalities in CD1d-null mice together with the enrichment of CD1d-restricted iNKT cells in both mouse and human adipose tissue indicated a specific role for adipose tissue-resident iNKT cells in the development of insulin resistance. Strikingly, iNKT cell function was directly modulated by adipocytes, which acted as lipid antigen-presenting cells in a CD1d-mediated fashion. Based on these findings, we propose that, especially under low-fat diet conditions, adipose tissue-resident iNKT cells maintain healthy adipose tissue through direct interplay with adipocytes and prevent insulin resistance.


Subject(s)
Insulin Resistance/immunology , Intra-Abdominal Fat/pathology , Natural Killer T-Cells/physiology , Subcutaneous Fat/pathology , Adipocytes/metabolism , Animals , Antigens, CD1d/genetics , Antigens, CD1d/metabolism , Cell Line , Coculture Techniques , Cytokines/genetics , Cytokines/metabolism , Diet, High-Fat , Down-Regulation , Gene Expression , Humans , Intra-Abdominal Fat/immunology , Intra-Abdominal Fat/physiopathology , Liver/metabolism , Liver/pathology , Lymphocyte Depletion , Mice , Mice, Inbred C57BL , Natural Killer T-Cells/metabolism , Oligonucleotide Array Sequence Analysis , Receptors, CCR2/metabolism , Subcutaneous Fat/immunology , Subcutaneous Fat/physiopathology , T-Lymphocytes, Regulatory/pathology , Transcriptome , Triglycerides/metabolism
8.
JIMD Rep ; 4: 47-54, 2012.
Article in English | MEDLINE | ID: mdl-23430896

ABSTRACT

BACKGROUND: Congenital generalized lipodystrophy (CGL) results from mutations in AGPAT2, encoding 1-acyl-glycerol-3-phosphate-acyltransferase 2 (CGL1; MIM 608594), BSCL2, encoding seipin (CGL2; MIM 269700), CAV1, encoding caveolin1 (CGL3; MIM 612526) or PTRF, encoding polymerase I and transcript release factor (CGL4; MIM 613327). This study aims to investigate the genotype/phenotype relationship and search for a possible pathogenic mechanism in a patient with CGL. DESIGN: Case report. PATIENTS AND SETTING: A 7-day-old child of consanguineous Turkish parents presented with a generalized loss of subcutaneous fat. He had a strikingly enlarged liver, high serum triglycerides, and hyperglycaemia, suggestive for CGL. RESULTS: A novel homozygous mutation in the acceptor splice site of exon 5 of the BSCL2 gene was found in the genome of the proband. This mutation causes a complex RNA splicing defect and results in two different aberrant seipin proteins, which were normally expressed and localized to the endoplasmic reticulum like wild type protein. Analysis of the patient's urine showed intermittent elevations of citric acid intermediates and persistently high concentrations of ethylmalonic acid, suggestive of a disturbance of the mitochondrial respiratory chain. CONCLUSION: Here we report abnormal urinary organic acid levels, indicative of mitochondrial dysfunction, in a patient with CGL resulting from a novel mutation in BSCL2. Our findings suggest for the first time an association between CGL and secondary mitochondrial dysfunction.

9.
J Biol Chem ; 284(39): 26385-93, 2009 Sep 25.
Article in English | MEDLINE | ID: mdl-19633298

ABSTRACT

The ligand-inducible nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) plays a key role in the differentiation, maintenance, and function of adipocytes and is the molecular target for the insulin-sensitizing thiazoledinediones (TZDs). Although a number of PPARgamma target genes that may contribute to the reduction of circulating free fatty acids after TZD treatment have been identified, the relevant PPARgamma target genes that may exert the anti-lipolytic effect of TZDs are unknown. Here we identified the anti-lipolytic human G-protein-coupled receptor 81 (GPR81), GPR109A, and the (human-specific) GPR109B genes as well as the mouse Gpr81 and Gpr109A genes as novel TZD-induced genes in mature adipocytes. GPR81/Gpr81 is a direct PPARgamma target gene, because mRNA expression of GPR81/Gpr81 (and GPR109A/Gpr109A) increased in mature human and murine adipocytes as well as in vivo in epididymal fat pads of mice upon rosiglitazone stimulation, whereas small interfering RNA-mediated knockdown of PPARgamma in differentiated 3T3-L1 adipocytes showed a significant decrease in Gpr81 protein expression. In addition, chromatin immunoprecipitation sequencing analysis in differentiated 3T3-L1 cells revealed a conserved PPAR:retinoid X receptor-binding site in the proximal promoter of the Gpr81 gene, which was proven to be functional by electromobility shift assay and reporter assays. Importantly, small interfering RNA-mediated knockdown of Gpr81 partly reversed the inhibitory effect of TZDs on lipolysis in 3T3-L1 adipocytes. The coordinated PPARgamma-mediated regulation of the GPR81/Gpr81 and GPR109A/Gpr109A genes (and GPR109B in humans) presents a novel mechanism by which TZDs may reduce circulating free fatty acid levels and perhaps ameliorate insulin resistance in obese patients.


Subject(s)
Adipocytes/metabolism , Gene Expression Regulation , PPAR gamma/genetics , Receptors, G-Protein-Coupled/genetics , 3T3-L1 Cells , Adipocytes/cytology , Adipocytes/drug effects , Animals , Base Sequence , Blotting, Western , Cell Differentiation/drug effects , Cells, Cultured , Chromatin Immunoprecipitation , Humans , Mice , Mice, Inbred Strains , Oligonucleotide Array Sequence Analysis , PPAR gamma/agonists , PPAR gamma/metabolism , Promoter Regions, Genetic/genetics , Protein Binding , RNA Interference , Receptors, G-Protein-Coupled/metabolism , Receptors, Nicotinic/genetics , Receptors, Nicotinic/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Rosiglitazone , Sequence Homology, Nucleic Acid , Thiazolidinediones/pharmacology
10.
Endocrinology ; 149(4): 1840-9, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18096664

ABSTRACT

The transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) plays a key role in the regulation of lipid and glucose metabolism in adipocytes, by regulating their differentiation, maintenance, and function. The transcriptional activity of PPARgamma is dictated by the set of proteins with which this nuclear receptor interacts under specific conditions. Here we identify the HIV-1 Tat-interacting protein 60 (Tip60) as a novel positive regulator of PPARgamma transcriptional activity. Using tandem mass spectrometry, we found that PPARgamma and the acetyltransferase Tip60 interact in cells, and through use of chimeric proteins, we established that coactivation by Tip60 critically depends on the N-terminal activation function 1 of PPARgamma, a domain involved in isotype-specific gene expression and adipogenesis. Chromatin immunoprecipitation experiments showed that the endogenous Tip60 protein is recruited to PPARgamma target genes in mature 3T3-L1 adipocytes but not in preadipocytes, indicating that Tip60 requires PPARgamma for its recruitment to PPARgamma target genes. Importantly, we show that in common with disruption of PPARgamma function, small interfering RNA-mediated reduction of Tip60 protein impairs differentiation of 3T3-L1 preadipocytes. Taken together, these findings qualify the acetyltransferase Tip60 as a novel adipogenic factor.


Subject(s)
Adipogenesis , Histone Acetyltransferases/physiology , PPAR gamma/physiology , 3T3-L1 Cells , Amino Acid Sequence , Animals , Cell Line, Tumor , Humans , Lysine Acetyltransferase 5 , Mice , Molecular Sequence Data , PPAR gamma/chemistry , Protein Structure, Tertiary , Transcription, Genetic
11.
Mol Endocrinol ; 21(5): 1049-65, 2007 May.
Article in English | MEDLINE | ID: mdl-17312272

ABSTRACT

The nuclear receptor peroxisome proliferator-activated receptor (PPAR) gamma plays a key role in the regulation of glucose and lipid metabolism in adipocytes by regulating their differentiation, maintenance, and function. A heterozygous mutation in the PPARG gene, which changes an arginine residue at position 425 into a cysteine (R425C), has been reported in a patient with familial partial lipodystrophy subtype 3 (FPLD3). The strong conservation of arginine 425 among nuclear receptors that heterodimerize with retinoic acid X receptor prompted us to investigate the functional consequences of the R425C mutation on PPARgamma function. Here we show that this mutant displayed strongly reduced transcriptional activity compared with wild-type PPARgamma, irrespective of cell type, promoter context, or ligand, whereas transrepression of nuclear factor-kappaB activity remained largely intact. Our data indicate that the reduced transcriptional activity of PPARgamma R425C is not caused by impaired corepressor release, but due to reduced dimerization with retinoic acid X receptor alpha in combination with reduced ligand binding and subsequent coactivator binding. As a consequence of these molecular defects, the R425C mutant was less effective in inducing adipocyte differentiation. PPARgamma R425C did not inhibit its wild-type counterpart in a dominant-negative manner, suggesting a haploinsufficiency mechanism in at least some FPLD3 patients. Using molecular dynamics simulations, substitution of R425 with cysteine is predicted to cause the formation of an alternative salt bridge. This structural change provides a likely explanation of how mutation of a single conserved residue in a patient with FPLD3 can disrupt the function of the adipogenic transcription factor PPARgamma on multiple levels.


Subject(s)
Lipodystrophy, Familial Partial/genetics , PPAR gamma/genetics , Amino Acid Substitution , Arginine , Base Sequence , Bone Neoplasms , Cell Line, Tumor , Cysteine , DNA/genetics , DNA Mutational Analysis , DNA Probes , Genetic Carrier Screening , Humans , Models, Molecular , Osteosarcoma , PPAR gamma/antagonists & inhibitors , PPAR gamma/chemistry , Protein Conformation , Transcription, Genetic , Transfection
12.
Pediatr Nephrol ; 20(3): 335-41, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15688232

ABSTRACT

Growth retardation is a serious side effect of long-term glucocorticoid (GC) treatment. In order to prevent or diminish this deleterious effect, a combination therapy including growth hormone (GH), a stimulator of bone growth, is often recommended. Parathyroid hormone (PTH) and thyroid hormone (T(4)) are important hormonal regulators of bone growth, and might also be helpful anabolic agents for counteracting the negative effects of GCs. Therefore, we studied the interaction of GCs in combination with a single dose of either PTH or T(4) on GC-induced growth retardation. Dexamethasone (Dex) treatment of mice for four weeks induced a significant growth inhibition of body length and weight and weights of several organs. PTH or T(4) alone did not affect the normal growth pattern. However, T(4) could partially restore the Dex-induced growth inhibition, whereas PTH could not. Although PTH did not affect total body growth, it did affect the height of the proliferative zone, which could be counteracted by Dex. This contrasts with T(4) treatment alone or in combination with Dex, which both resulted in a disturbed morphology of the growth plate. IGF-I mRNA, one of the mediators of longitudinal bone growth, was present in proliferative and hypertrophic chondrocytes. However, its expression was not affected by any of the treatments. In conclusion, T(4) but not PTH can partially counteract the effects of Dex on general body growth, with possible implications for future treatments of GC-induced growth retardation. Additionally, both T(4) and PTH, alone or in combination with Dex, have differential effects on the morphology of the growth plate.


Subject(s)
Growth Disorders/drug therapy , Parathyroid Hormone/therapeutic use , Thyroxine/therapeutic use , Animals , Dexamethasone/analogs & derivatives , Dexamethasone/pharmacology , Female , Glucocorticoids/pharmacology , Growth Disorders/chemically induced , Mice
13.
Clin Chem Lab Med ; 43(1): 71-4, 2005.
Article in English | MEDLINE | ID: mdl-15653446

ABSTRACT

Dextran interference in biuret-type assays of total serum proteins was investigated in a Belgian National External Quality Assurance Survey with 256 participants. In vitro supplementation of therapeutic (10% Gentran 70) dextran concentrations showed a broadly varying (from 0 to 20%) negative interference. The analytical interference was found to depend on both the sodium hydroxide and tartrate concentrations in the reagent formulation. The dry chemistry biuret method was not affected by the dextran interference. In a number of cases, the effects observed may be of clinical importance. Both clinicians and laboratory staff should be aware of the persistence of this analytical problem.


Subject(s)
Biuret Reaction/methods , Blood Proteins/analysis , Dextrans/chemistry , Clinical Chemistry Tests , Humans , Plasma Substitutes/chemistry , Reagent Kits, Diagnostic , Regression Analysis
14.
Clin Chem Lab Med ; 42(11): 1341-5, 2004.
Article in English | MEDLINE | ID: mdl-15576294

ABSTRACT

Analysis of blood of severely intoxicated patients always requires prompt investigation. Diagnosis of intoxication with ethylene glycol, gamma-hydroxybutyric acid or D-lactic acid takes hours, since several different procedures are required. Rapid derivatization of the common hydroxyl function may resolve this analytical problem. Here we describe a fast method for the simultaneous measurement of ethylene glycol, glycolic acid, gamma-hydroxybutyric acid and racemic lactic acid. Only 20 microl of serum, plasma or urine are required for immediate derivatization at 70 degrees C with 750 microl of bis-N,O-trimethylsilyl trifluoroacetamide after adding 20 microl of internal standard solution (1,3-propylene glycol) and 20 microl of the catalyst dimethylformamide. After centrifugation an aliquot is transferred to a gas chromatographic system and analyzed with electron-impact mass spectrometry in selective ion monitoring mode. The derivatized acids and ethylene glycol are well separated and detected with a limit of detection ranging from 0.12 mg/l for ethylene glycol to 0.95 mg/l for gamma-hydroxybutyric acid, while the limit of quantification ranged from 0.4 mg/l for ethylene glycol to 3.15 mg/l for gamma-hydroxybutyric acid. The method is linear from 0.5 to 1800 mg/l blood for ethylene glycol, from 0.7 to 1200 mg/l for lactic acid, from 1.2 to 1800 mg/l for glycolic acid, and from 3.2 to 200 mg/l for gamma-hydroxybutyric acid, with analytical recoveries, accuracy, day-to-day and within-day precision well within the required limits. Total analysis time with one calibrator was 30 min, derivatization time included. This method is very suitable for emergency toxicology, since several toxic substances can be quantified simultaneously in a fast and sensitive manner.


Subject(s)
Ethylene Glycol/analysis , Gas Chromatography-Mass Spectrometry/methods , Glycolates/analysis , Hydroxybutyrates/analysis , Lactic Acid/analysis , Mass Spectrometry/methods , Chromatography , Glycols/chemistry , Humans , Ions , Kinetics , Sensitivity and Specificity , Time Factors , Trimethylsilyl Compounds/chemistry
15.
Dev Neurosci ; 24(5): 396-404, 2002.
Article in English | MEDLINE | ID: mdl-12640178

ABSTRACT

Selective inhibition of neuronal and inducible nitric oxide synthase (NOS) with 2-iminobiotin previously showed a reduction in brain cell injury. In the present study, we investigated the effects of 2-iminobiotin treatment on insulin-like growth factor-1 (IGF-1) expression, caspase activity and cytokine expression in a newborn piglet model of perinatal hypoxia-ischaemia. Newborn piglets were subjected to 1 h of hypoxia-ischaemia and were treated intravenously with vehicle or 2-iminobiotin. Vehicle-treated piglets showed reduced IGF-1 mRNA expression and increased caspase-3 activity and DNA fragmentation. 2-Iminobiotin treatment, administered immediately upon reperfusion, prevented these observations. No differences in caspase-8 and -9 activity and cytokine [interleukin (IL)-1alpha/beta, IL-6, tumour necrosis factor (TNF)-alpha, transforming growth factor (TGF)-beta] mRNA expression were demonstrated between vehicle- and 2-iminobiotin-treated piglets at 24 h following hypoxia-ischaemia. IGF-1 mRNA correlated inversely with caspase-3 and transferase-mediated dUTP-biotin in situ nick end labelling score in the cortex, but positively with caspase-8. Cytokine mRNA did not correlate with IGF-1 mRNA, caspase-3 activity or DNA fragmentation. The present results indicate that the previously demonstrated neuroprotective effect of 2-iminobiotin treatment after perinatal hypoxia-ischaemia coincided with a preservation of the endogenous IGF-1 production and reduced caspase-3 activity, but not with a significant decrease in cytokine production.


Subject(s)
Biotin/analogs & derivatives , Biotin/pharmacology , Brain/drug effects , Enzyme Inhibitors/pharmacology , Hypoxia-Ischemia, Brain/metabolism , Animals , Animals, Newborn , Brain/metabolism , Brain/pathology , Caspases/metabolism , Cytokines/metabolism , DNA Fragmentation/drug effects , Enzyme Activation/drug effects , In Situ Nick-End Labeling , Insulin-Like Growth Factor I/biosynthesis , Models, Animal , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase Type I , Nitric Oxide Synthase Type II , Primed In Situ Labeling , RNA, Messenger/analysis , Swine
SELECTION OF CITATIONS
SEARCH DETAIL